Compare Monster Beverage Corp (MNST) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Monster Beverage Corp trades at $42.93 (market cap $84.53B), while State Street SPDR S&P Biotech ETF trades at $159.8. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Monster Beverage Corp nearer its low. Which is the better fit depends on your goals.
| MNST | XBI | |
|---|---|---|
Market Cap | $84.53B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $49.97 | $169.55 |
52-Week Low | $31.41 | $93.43 |
Enterprise Value | $82.83B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.15, down 1.53% on the day, following a recent 2-for-1 stock split completed August 11, 2026. The stock shows strong fundamental performance with revenue growing from $6.3B in 2022 to $8.3B in 2025, while net income expanded to $1.91B. Technical indicators present a mixed picture with bullish oscillators but bearish moving averages, creating uncertainty in the near-term direction. Analyst consensus remains positive with 51% buy ratings and a $51.10 price target representing 18% upside potential.
MNST offers compelling growth prospects driven by 20%+ revenue growth and expanding international presence (46% of Q2 2026 sales). However, elevated valuation multiples (P/E 39.95, P/S 9.24) and rising cost pressures present risks. The company's consistent earnings beats and strong cash flow generation support the bullish case, but investors should weigh growth potential against premium valuation in a competitive beverage market.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
